Expertise in
5
conditions

William H. Yang

2036 Main Mall, V6T 1Z1, 
Vancouver, BC, CA 
Expertise in
5
conditions
2036 Main Mall, V6T 1Z1, 
Vancouver, BC, CA 

Overview

William Yang practices practicing medicine in Vancouver, Canada.

Mr. Yang is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Angioedema, Hereditary Angioedema, Hives, and Asthma.

He is actively involved in clinical research, co-authoring 48 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

2036 Main Mall, V6T 1Z1, Vancouver, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Expanded Access Program: Lanadelumab for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Patients 2 to <12 Years of Age and Lanadelumab for the Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: No_longer_available
Publish Date: July 24, 2023
Intervention Type: Drug
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age
Enrollment Status: Completed
Publish Date: May 26, 2022
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Biological
Study Phase: Phase 3
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Safety Study of Viaskin Peanut to Treat Peanut Allergy
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 6 Less Clinical Trials

48 Total Publications

Rapid access to sulfinyl fluorides for the preparation of sulfonimidoyl fluorides.
Rapid access to sulfinyl fluorides for the preparation of sulfonimidoyl fluorides.
Journal: Chemical communications (Cambridge, England)
Published: June 23, 2026

Frequently Asked Questions about William H. Yang

Is William H. Yang a top-rated expert for Angioedema?

MediFind is an objective health platform that identifies experts based on real-world data. William H. Yang is classified as an Elite expert for Angioedema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does William H. Yang participate in research or clinical trials?

Yes. William H. Yang has published 48 articles and abstracts on conditions like Angioedema. You can view a list of William H. Yang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yang's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile